4D Molecular Therapeutics, Inc. (FDMT)

NASDAQ: FDMT · IEX Real-Time Price · USD

14.40

-0.74 (-4.89%)

At close: Jul 19, 2024, 4:00 PM

14.88

+0.48 (3.33%)

Pre-market: Jul 22, 2024, 9:10 AM EDT

4D Molecular Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	2018
Net Income	-104.56	-100.84	-107.49	-71.32	-56.69	-49.31	Upgrade
Depreciation & Amortization	5.93	5.75	3.88	3.02	1.44	1	Upgrade
Share-Based Compensation	21.42	19.67	17.12	13.8	4.98	3.54	Upgrade
Other Operating Activities	0.23	-0.37	-0.19	-14.64	-0.64	8.05	Upgrade
Operating Cash Flow	-76.97	-75.79	-86.69	-69.13	-50.91	-36.71	Upgrade
Capital Expenditures	-2.47	-2.77	-11.54	-9.11	-1	-3.2	Upgrade
Change in Investments	-188.2	118.49	-5.51	-163.57	0	0	Upgrade
Investing Cash Flow	-190.67	115.72	-17.05	-172.68	-1	-3.2	Upgrade
Share Issuance / Repurchase	464.6	156.83	3.55	118.09	206.52	-2.19	Upgrade
Other Financing Activities	0.07	-	-0.47	-	72.47	-0.01	Upgrade
Financing Cash Flow	464.67	156.83	3.09	118.09	278.98	-2.2	Upgrade
Net Cash Flow	197.03	196.76	-100.65	-123.73	227.07	-42.11	Upgrade
Free Cash Flow	-79.44	-78.56	-98.22	-78.24	-51.91	-39.91	Upgrade
Free Cash Flow Margin	-388.44%	-379.11%	-3139.05%	-433.77%	-381.35%	-571.34%	Upgrade
Free Cash Flow Per Share	-1.61	-2.01	-3.04	-2.82	-8.07	-7.76	Upgrade

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).